FIGURE 7.

Akt/GSK3β/β-catenin signaling promotes SCD1-induced TMZ resistance. (A,B) T98G and U87 cells treated with pcDNA-SCD1, EGF or pcDNA-SCD1 plus EGF subjected to MTS assays. (C,D) Cell viability assays were performed after treating T98G-R and U87-R cells with anSCD1 inhibitor (A939572), Akt inhibitors (MK2206 and LY294002) or a combination of A939572 and Akt inhibitors. (E,F) Wound healing assay images captured after treating T98G-R and U87-R cells with A939572, MK2206, LY294002 or a combination of A939572 and Akt inhibitors for 0, 24, and 48 h. Experiments were repeated three times with similar results. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.